Trends in Cardiovascular Medicine
Volume 17, Issue 4 , Pages 129-133 , May 2007

α-Galactosidase A in Vascular Disease

  • Peter F. Bodary

      Affiliations

    • Department of Nutrition and Food Science, Wayne State University, Detroit MI 48202, USA
    • ,
  • James A. Shayman

      Affiliations

    • Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    • ,
  • Daniel T. Eitzman

      Affiliations

    • Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    • Corresponding Author InformationAddress correspondence to: Dr. Daniel T. Eitzman, MD, 1150 W. Medical Center Dr, 7301 MSRB III, Ann Arbor, MI 48109-0644, USA. Tel.: (+1 ) 734-763-7838; fax: (+1 ) 734-936-2641

References 

  1. Abe A, Gregory S, Lee L, et al. Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J Clin Invest. 2000;105:1563–1571
  2. Altarescu G, Moore DF, Schiffmann R. Effect of genetic modifiers on cerebral lesions in Fabry disease. Neurology. 2005;64:2148–2150
  3. Anderson W. A case of “angio-keratoma”. Br J Dermatol. 1898;10:113–117
  4. Ashton-Prolla P, Tong B, Shabbeer J, et al. Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J Investig Med. 2000;48:227–235
  5. Becker AE, Schoorl R, Balk AG, van der Heide RM. Cardiac manifestations of Fabry's disease. Report of a case with mitral insufficiency and electrocardiographic evidence of myocardial infarction. Am J Cardiol. 1975;36:829–835
  6. Bierer G, Kamangar N, Balfe D, et al. Cardiopulmonary exercise testing in Fabry disease. Respiration. 2005;72:504–511
  7. Bodary PF, Shen Y, Vargas FB, et al. Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation. 2005;111:629–632
  8. Brady RO, Gal AE, Bradley RM, et al. Enzymatic defect in Fabry's disease. Cereamidetrihexosidase deficiency. N Engl J Med. 1967;276:1163–1167
  9. Chatterjee S. Sphingolipids in atherosclerosis and vascular biology. Arterioscler Thromb Vasc Biol. 1998;18:1523–1533
  10. Cui J, Eitzman DT, Westrick RJ, et al. Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood. 2000;96:4222–4226
  11. Dawson G, Kruski AW, Scanu AM. Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976;17:125–131
  12. Dawson G, Sweeley CC. In vivo studies on glycosphingolipid metabolism in porcine blood. J Biol Chem. 1970;245:410–416
  13. Desnick RJ, Ioannou YA,, Eng CM, et al. Alpha-galactosidase A deficiency: Fabry Disease. In:  Scriver CR, et al. editor. The metabolic and molecular bases of inherited disease. 8th ed.. New York: McGraw-Hill; 2001;p. 3733–3774
  14. Desnick RJ, Allen KY,, Simmons RL, et al. Fabry disease: correction of the enzymatic deficiency by renal transplantation. Birth Defects Orig Artic Ser. 1973;9:88–96
  15. Dvorak AM, Cable WJ, Osage JE, Kolodny EH. Diagnostic electron microscopy. II. Fabry's disease: use of biopsies from uninvolved skin. Acute and chronic changes involving the microvasculature and small unmyelinated nerves. Pathol Annu. 1981;16(Pt 1):139–158
  16. Eitzman DT, Bodary PF, Shen YC, et al. Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis. J Am Soc Nephrol. 2003;14:298–302
  17. Eitzman DT, Westrick RJ, Bi X, et al. Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency and factor V Leiden. Circulation. 2002;105:2139–2142
  18. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease. N Engl J Med. 2001;345:9–16
  19. Fabry J. Ein Beitrag zur Kenntnis der Purpura haemorrhagica nodularis. Arch Dermatol Syph. 1898;111:187–200
  20. Ferrans VJ, Hibbs RG, Burda CD. The heart in Fabry's disease. A histochemical and electron microscopic study. Am J Cardiol. 1969;24:95–110
  21. Fisher EA, Desnick RJ, Gordon RE, et al. Fabry disease: an unusual cause of severe coronary disease in a young man. Ann Intern Med. 1992;117:221–223
  22. Friedman GS, Wik D, Silva L, et al. Allograft loss in renal transplant recipients with Fabry's disease and activated protein C resistance. Transplantation. 2000;69:2099–2102
  23. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104:503–516
  24. Goldstein JL, Brown MS. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem. 1977;46:897–930
  25. Grewal RP. Stroke in Fabry's disease. J Neurol. 1994;241:153–156
  26. Hakomori S, Igarashi Y. Functional role of glycosphingolipids in cell recognition and signaling. J Biochem (Tokyo). 1995;118:1091–1103
  27. Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ. Fabry disease: preclinical studies demonstrate the effectiveness of α-galactosidase A preplacement in enzyme-deficient mice. Am J Hum Genet. 2001;68:14–25
  28. Jung SC, Han IP, Limaye A, et al. Adeno-associated vira vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs ofFabry mice. Proc Natl Acad Sci. 2001;98:2676–2681
  29. Levade T, Giordano F, Maret A, et al. Different phenotypic expression of Fabry disease in female monozygotic twins. J Inherit Metab Dis. 1991;14:105–106
  30. Mitsias P, Levine SR. Cerebrovascular complications of Fabry's disease. Ann Neurol. 1996;40:8–17
  31. Moore DF, Scott LTC, Gladwin MT, et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease. Circulation. 2001;104:1506–1512
  32. Mukhin DN, Chao FF, Kruth HS. Glycosphingolipid accumulation in the aortic wall is another feature of human atherosclerosis. Atheroscler Thromb Vasc Biol. 1995;15:1607–1615
  33. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessmentstrategies: Part 1. Circulation. 2003;108:1664–1672
  34. Nakamura T, Kaneko H, Nishino I. Angiokeratoma corporis diffusum (Fabry disease): ultrastructural studies of the skin. Acta Derm Venereol. 1981;61:37–41
  35. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med. 1995;333:288–293
  36. Ohshima T, Schiffmann R, Murray GJ, et al. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc Natl Acad Sci U S A. 1999;96:6423–6427
  37. Pompen AWM, Ruiter M, Wyers HJG. Angiokeratoma corporis diffusum (universale) Fabry, as a sign of an unknown internal diseases; two autopsy reports. Acta Med Scand. 1947;128:234–255
  38. Puccio D, Coppola G, Corrado E, et al. Non invasive evaluation of endothelial function in patients with Anderson-Fabry disease. Int Angiol. 2005;24:295–299
  39. Rolfs A, Bottcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005;366:1794–1796
  40. Schiffmann R, Kopp JB, Austin HA, et al. Enzyme replacement therapy in Fabry disease (a randomized controlled trial). JAMA. 2001;285:2743–2749
  41. Schiffmann R, Rapkiewicz A, bu-Asab M, et al. Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch. 2006;448:337–343
  42. Shen Y, Bodary PF, Vargas FB, et al. alpha-Galactosidase A deficiency leads to increased tissue fibrin deposition and thrombosis in mice homozygous for the factor V Leiden mutation. Stroke. 2006;37:1106–1108
  43. Sheth KJ, Roth DA, Adams MB. Early renal failure in Fabry's disease. Am J Kidney Dis. 1983;2:651–654
  44. Skipski VP, Barclay M, Barclay RK, et al. Lipid composition of human serum lipoproteins. Biochem J. 1967;104:340–352
  45. Svensson PJ. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517–522
  46. Sweeley CC, Klionsky B. Fabry's disease: classification as a sphyngolipidosis and partial characterisation of a novel glycolipid. J Biol Chem. 1963;238:3148–3150
  47. Utsumi K, Yamamoto N, Kase R, et al. High incidence of thrombosis in Fabry's disease. Intern Med. 1997;36:327–329
  48. Van Loo A, Vanholder R, Madsen K, et al. Novel frameshift mutation in a heterozygous woman with Fabry disease and end-stage renal failure. Am J Nephrol. 1996;16:352–357

PII: S1050-1738(07)00050-3

doi: 10.1016/j.tcm.2007.02.006

Trends in Cardiovascular Medicine
Volume 17, Issue 4 , Pages 129-133 , May 2007

Article Tools

* Image Usage & Resolution